In vitro study | AZD1152 acts on Aurora B more than 3000 times more selective than Aurora A, IC50 is 1.368 μm. AZD1152 acts on 50 other serine-threonine and tyrosine kinases, including FLT3, JAK2, and Abl with lower activity. AZD1152 inhibits the proliferation of hematopoietic malignant cells, such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells, with an IC50 of 3-40 nM, the effect is more than 100 times higher than that of another Aurora kinase inhibitor, ZM334739, with an IC50 of 3-30 μm. AZD1152 inhibited the growth of MOLM13 and MV4-11 cell clones with IC50 of 1 nM and 2.8 nM, respectively, and also inhibited newly isolated leukemic cells resistant to Imatinib with IC50 of 1-3 nM, more effective than on bone marrow mononuclear cells, IC50>10 nM. AZD1152 induced accumulation of cells carrying 4N/8N DNA followed by apoptosis in a dose-and time-dependent manner. |
In vivo study | AZD1152 treated MOLM13 xenografts alone at a dose of 25 mg/kg significantly inhibited tumor growth, with an average tumor volume from 1261mm, treatment of AZD1152 at doses of 10-150 mg/kg per day in a variety of solid human xenografts, including colon, breast, and lung cancers, significantly inhibited tumor growth in a dose-dependent manner. |